| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | Pivekimab sunirine (PVEK) | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | PDUFA | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | trenibotulinumtoxinE (TrenibotE) | Moderate to severe glabellar lines | PDUFA | Ongoing | Intramuscular | N/A |
| AbbVie Inc. | Tavapadon - (TEMPO-2) | Parkinson's disease | PDUFA | Ongoing | Oral | Neurology |
| AbbVie Inc. | Tavapadon - (TEMPO-2) | Parkinson's disease | PDUFA | Ongoing | Oral | Neurology |
| AbbVie Inc. | trenibotulinumtoxinE (TrenibotE) | Moderate to severe glabellar lines | PDUFA | Ongoing | Intramuscular | N/A |
| AbbVie Inc. | Pivekimab sunirine (PVEK) | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | PDUFA | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | telisotuzumab-vedotin (Teliso-V) | Advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) | BLA Filing | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | VENCLEXTA (venetoclax) and acalabrutinib - (AMPLIFY) | Chronic Lymphocytic Leukemia (CLL) | sNDA Filing | Ongoing | Oral | Oncology |